By vgreene, 5 June, 2019 PAM50: recommended only in pts w/ node-negative status AND in conjunction w/ other clinicopathologic variables to guide decisions about adjuvant systemic tx2 [ASCO EV-high; REC-strong]
By vgreene, 5 June, 2019 MammaPrint assay: recommended in pts w/ node-negative status [ASCO EV-high; REC-strong] or pts w/ 1-3 positive nodes [ASCO EV-high; REC-moderate] who ALSO have high clinical risk as defined by MINDACT categorization to inform decisions on withholding adju
By vgreene, 5 June, 2019 Oncotype DX 21-gene RS: preferred, but only in pts w/ node-negative status1,2); not recommended if node-positive2 [ASCO EV-high; REC-strong]